Key Highlights

  • Hikma Pharmaceuticals Plc (LSE:HIK) gained 2.60% on 6 October 2026 as drugmakers rose in London.
  • First-half Revenue increased 4% to $1.73 billion, while core operating profit grew 9% to $405 million.
  • Hikma reaffirmed 2026 guidance for revenue growth of 2% to 4% and core operating profit of $720 million to $770 million.
  • A $250 million share buyback and a 6% higher Interim Dividend support Shareholder returns.

Hikma Shares Advance on 6 October

Hikma Pharmaceuticals Plc (LSE:HIK), the multinational maker of generic, branded and injectable medicines, closed 2.60% higher on Tuesday, 6 October 2026.

London shares closed higher on Tuesday, 6 October 2026, with the FTSE 100 adding 0.4% to 10,541.69 and the FTSE 250 rising 0.4% to 24,215.33. Brent Crude slipped back below $100 a barrel to around $98.37, down from $102.32 a day earlier, after Saudi-backed forces regained control of the Bab el-Mandeb Strait and signs emerged of improving oil flows through the Gulf. Cooler oil prices calmed bond markets, with the US 10-year Treasury Yield easing to 5.27% from 5.33%, while the S&P 500 set a fresh all-time high.

Pharmaceutical shares were among the sectors leading the early rally in London, with AstraZeneca also posting gains of more than 2% during the morning session, creating a supportive backdrop for Hikma.

Why Hikma Is in Focus

Hikma has been rebuilding investor confidence after scrapping its medium-term targets in February because of challenges in its injectables division and US Manufacturing delays. Under chief executive Said Darwazah, the company has been expanding its product range and tightening operations.

Interim results on 6 August 2026 showed the strategy gaining traction. Revenue rose 4% to $1.73 billion and core operating profit grew 9% to $405 million, beating some analyst expectations. Branded revenue increased 15%, supported by performance in markets such as Saudi Arabia and a focus on chronic illness treatments. The shares jumped as much as 10.3% to £17.33 that day, their best daily gain since September 2022.

Hikma maintained full-year guidance for currency-adjusted revenue growth of 2% to 4% and core operating profit of $720 million to $770 million, which some analysts viewed as potentially conservative.

Key Reasons Behind the Share Price Gain

Defensive growth. In a market still wary of Inflation and higher interest rates, steady Earnings from medicines appeal to investors seeking resilience.

Shareholder returns. Hikma raised its interim dividend by 5.6% to 38 cents per share and continues a $250 million buyback launched in February 2026.

US capacity build-out. The company plans to spend $267 million to expand manufacturing in Columbus and Bedford, Ohio, creating around 350 jobs across injectable, oral solid dose and nasal inhalation facilities. Domestic US production can help mitigate potential tariffs on imported generics.

Divisional Picture

Hikma expects Injectables revenue to grow at a low single-digit rate in 2026 with a core Operating Margin of 27% to 28%, supported by Demand for products such as Tyzavan. The Branded Business is guided to grow 6% to 8% with a margin of about 25%, while Hikma Rx revenue is expected to be broadly flat with a margin close to 20%. Recent launches include a generic version of Xeljanz oral solution in the US. Net Debt rose to $1.69 billion at 30 June, reflecting Investment and buybacks.

What Investors Are Watching

Investors will monitor US Tariff decisions on generic drugs, progress at the Ohio expansion, new product approvals, Middle East demand and trends in US injectables pricing. Full-year results in early 2027 will show whether core profit lands at the upper end of guidance.

Risks include pricing pressure, manufacturing issues, regulatory actions and regional geopolitical instability.

Outlook

Hikma Pharmaceuticals Plc (LSE:HIK) is delivering steady core profit growth while expanding US capacity and returning cash to shareholders. Tuesday's 2.60% gain shows the stock benefiting from both sector strength and improving confidence in its recovery.